Jody A. Charnow

Editor

Jody A. Charnow has been the editor of Renal & Urology News, a publication of Haymarket Media, since 2003. Previously, he had served as editor of Internal Medicine World Report and a managing editor for Medical Tribune. He holds a BA in biology from the State University of New York at Albany.

All articles by Jody A. Charnow

A scientist placing a slide under a microscope

Prostate Cancer

Prostate Cancer Recurrence After Surgery Linked to Pelvic Inflammation

Jody A. Charnow

July 26, 2022

A recent study is the first to examine the association between pelvic inflammation and prostate cancer biology and outcomes.

Prostate Cancer

Study: 68Ga-PSMA-11 PET May Miss Pelvic Nodal Metastasis in Prostate Cancer

Jody A. Charnow

October 13, 2021

68Ga-PSMA-11 PET scans have a 40% sensitivity for detecting pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer, data show.

Bladder Cancer

First-Line Immunotherapy, Chemotherapy for mUC of the Bladder Offer Similar Survival

Jody A. Charnow

September 2, 2021

Real-world data validate recently reported findings from clinical trials.

Bladder Cancer

Data Support Ureteroscopy for Upper Tract Urothelial Carcinoma

Jody A. Charnow

August 26, 2020

Patients who underwent ureteroscopic management of low-risk UTUC had a 5-year cancer-specific survival rate of 92.6%.

Bladder Cancer

Survival Remains Poor in High-Risk Muscle-Invasive Urothelial Carcinoma

Jody A. Charnow

August 18, 2020

Overall and disease-free survival among patients undergoing surgical resection for MIUC is low despite increasing use of neoadjuvant chemotherapy.

Uncategorized

Pembrolizumab Benefits Durable in BCG-Unresponsive High-Risk NMIBC

Jody A. Charnow

May 29, 2020

After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.

Though early-stage bladder cancer is infrequently fatal, the decrease in recurrence rates has a mean

Uncategorized

5-ARIs Do Not Lower Bladder Cancer Risk

Jody A. Charnow

May 22, 2020

Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.

Prostate Cancer

PARP Inhibitor Approved for BRCA-Mutated mCRPC

Jody A. Charnow

May 19, 2020

FDA has approved rucaparib for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in men previously treated with androgen-receptor directed therapy and taxane-based chemotherapy.